This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Globus Medical (GMED) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Globus Medical (GMED) delivered earnings and revenue surprises of 5% and 3.37%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
LivaNova (LIVN) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
LivaNova (LIVN) delivered earnings and revenue surprises of 34.48% and 10.30%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Abbott (ABT) EPD Sales Gain Traction, Margin Pressure Lingers
by Zacks Equity Research
Abbott (ABT) continues to make good progress in Nutrition, increasing manufacturing production and recovering market share in this business.
LabCorp (LH) Gives Update as Fortrea Spinoff Nears Closure
by Zacks Equity Research
Fortrea is set to comprise Labcorp's (LH) Clinical Development and Commercialization Services businesses.
Illumina (ILMN) Sequencing Arm Grows, Margin Woes Linger
by Zacks Equity Research
Illumina's (ILMN) total sequencing activity on connected high- and mid-throughput instruments are growing strongly.
Charles River (CRL) to Aid INADcure in Plasmid DNA Manufacture
by Zacks Equity Research
Charles River (CRL) collaborates with INADcure Foundation on plasmid DNA manufacturing for developing treatments for INAD patients.
Bruker (BRKR) Launches timsTOF Ultra Mass Spec and VistaScan
by Zacks Equity Research
Bruker (BRKR) introduces the timsTOF Ultra mass spectrometer and VistaScan software for enhanced dia-PASEF 4D-Proteomics at the 71st ASMS meeting.
Quest Diagnostics' (DGX) Contract Wins Aid Amid Volume Woes
by Zacks Equity Research
Quest Diagnostics (DGX) succeeds on contract wins in its reference and professional lab services offerings.
Bruker's (BRKR) Latest Workflows to Aid Applied Markets
by Zacks Equity Research
Bruker (BRKR) introduces Novel EVOQ DART-TQ+ for chromatography-free mass spectrometry for applied markets.
Walgreens Boots (WBA) Gains From New Alliances Amid Macro Woes
by Zacks Equity Research
Continued slowdown in generic introduction has been affecting Walgreens Boots' (WBA) margins.
Neogen (NEOG) Introduces 2 Assays for Histamine Detection
by Zacks Equity Research
Neogen (NEOG) launches Reveal for Histamine and Reveal Q+ for Histamine assays for the detection of Histamine.
LabCorp (LH) Expands Precision Oncology With Biopsy Test
by Zacks Equity Research
The addition of Labcorp Plasma Focus marks a pivotal step in the expansion of LabCorp's (LH) suite of precision oncology tests.
Illumina (ILMN) to Present Real-World CGP Data at ASCO Meet '23
by Zacks Equity Research
At the ASCO meeting, Illumina (ILMN) is set to showcase data that highlights better outcomes for cancer patients who receive comprehensive genomic testing.
Medtronic's (MDT) EV ICD Pivotal Study Shows Favorable Outcome (Revised)
by Zacks Equity Research
Medtronic (MDT) announces that the findings of the EV ICD Pivotal Study reinforce device safety and effectiveness.
Myriad Genetics (MYGN) Adds New Test to Oncology Portfolio
by Zacks Equity Research
Myriad Genetics (MYGN) expands Precise Oncology Solutions portfolio by adding a new biomarker test.
Medtronic's (MDT) EV ICD Pivotal Study Shows Favorable Outcome
by Zacks Equity Research
Medtronic (MDT) announces that the findings of the EV ICD Pivotal Study reinforce device safety and effectiveness.
Exact Sciences (EXAS) Gains From New Buyouts Amid High Costs
by Zacks Equity Research
Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is now offering therapy selection tests for patients with advanced cancer.
Thermo Fisher (TMO) Gets FDA Clearance for Its Immunoassays
by Zacks Equity Research
Thermo Fisher (TMO) announces the FDA clearance of its blood-based biomarkers used in the determination of risk assessment and clinical management of preeclampsia with severe features.
Illumina (ILMN) Progresses in Pathogen Genomic Technologies
by Zacks Equity Research
Illumina's (ILMN) genomic surveillance solutions enable better pathogen preparedness and response.
Hologic (HOLX) Announces Collaboration With NFL CB Kelee Ringo
by Zacks Equity Research
Hologic (HOLX) and Eagles' CB, Kelee Ringo, come together to highlight the importance of annual mammograms and other routine health screenings.
Integra (IART) Builds Advanced R&D Facility in New Jersey
by Zacks Equity Research
Integra (IART) opens the Dr. Richard E. Caruso Center of Innovation and Learning in New Jersey.
Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Neuronetics (STIM) delivered earnings and revenue surprises of 2.56% and 2.85%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Neuronetics (STIM) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Neuronetics (STIM) delivered earnings and revenue surprises of 30.23% and 9.76%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
5 Winning Medical Product Stocks That Still Have Room to Run
by Indrajit Bandyopadhyay
Despite ongoing macro challenges, medical product stocks like Cardinal Health (CAH), TransMedics Group (TMDX), Olink Holding (OLK), Silk Road Medical (SILK) and Neuronetics (STIM) are likely to gain from strong fundamentals.
Is Neuronetics (STIM) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Neuronetics (STIM) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.